Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease

Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD). The minimal pathologic criteria for NASH include hepatic steatosis, ballooning degeneration, and lobular inflammation. The resolution of NASH, which relies on the loss of ballooning degeneration, is subject to sampling and observer variability in pathologic interpretation. Ballooning is associated with advanced hepatic fibrosis in cross‐sectional studies but is not a predictor of mortality in NAFLD. Fibrosis staging, while still subject to some sampling variability, has less observer variability and is a robust predictor of liver‐related mortality in NAFLD. In this study, we hypothesize that, regardless of the diagnosis of NASH, the presence of steatofibrosis (steatosis accompanied by fibrosis) regardless of other pathologic features can also be a robust predictor of mortality in NAFLD. We used our previously reported cohort of patients with NAFLD with liver biopsies and long‐term mortality follow‐up. Cox proportional hazard models were used to determine the predictors of overall and liver‐related mortality. Of 209 enrolled NAFLD subjects, 97 can be classified as having steatofibrosis. During follow‐up (median 150 months), 64 (30.6%) patients died, with 18 (8.6%) from liver‐related causes. Adjusted for age, both diagnostic categories of NASH and steatofibrosis were significantly and similarly associated with liver‐related mortality (adjusted hazard ratio [aHR], 9.9; 95% confidence interval (CI), 1.3‐74.9; P = 0.027; aHR, 6.7; 95% CI, 1.5‐29.8; P = 0.013, respectively). However, only steatofibrosis showed independent association with overall mortality (aHR, 1.76; 95% CI, 1.02‐3.05; P = 0.043). Conclusion: Steatofibrosis and NASH are similarly associated with liver‐related mortality, but only steatofibrosis is associated with overall mortality in patients with NAFLD. Given the inherent observer variability in ballooning degeneration, a key diagnostic component of NASH, we suggest that steatofibrosis should be considered a viable diagnostic classification for NAFLD subjects at risk or adverse outcomes and provides a simpler endpoint for clinical trials of therapeutic agents. (Hepatology Communications 2017;1:421–428)

[1]  J. Dufour,et al.  The therapeutic landscape of non‐alcoholic steatohepatitis , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[2]  P. Bedossa,et al.  SAF score and mortality in NAFLD after up to 41 years of follow-up , 2017, Scandinavian journal of gastroenterology.

[3]  V. Wong,et al.  Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients , 2017, Hepatology.

[4]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[5]  Bin Zhang,et al.  Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  Rohit Loomba,et al.  MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. , 2016, Journal of hepatology.

[7]  Lingling He,et al.  Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials , 2016, Medicine.

[8]  M. Stepanova,et al.  Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease , 2016, BMJ open gastroenterology.

[9]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[10]  L. Henry,et al.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 , 2015, Hepatology.

[11]  D. Kleiner,et al.  Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. , 2015, Gastroenterology.

[12]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[13]  N. Chalasani,et al.  The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. , 2015, Gastroenterology.

[14]  G. Sebastiani,et al.  Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis , 2015, PloS one.

[15]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[16]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[17]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[18]  S. Saab,et al.  The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. , 2014, JAMA internal medicine.

[19]  H. Makhlouf,et al.  Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, Digestive Diseases and Sciences.

[20]  A. McCullough,et al.  Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. , 2012, Gastroenterology & hepatology.

[21]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[22]  D. Mann,et al.  Clinical evidence for the regression of liver fibrosis. , 2012, Journal of hepatology.

[23]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[24]  H. Makhlouf,et al.  Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality , 2011, Hepatology.

[25]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[26]  P. Angulo.  Long‐term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? , 2010, Hepatology.

[27]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[29]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[30]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[31]  D. Kleiner,et al.  Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. , 2004, Human pathology.

[32]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[33]  J. Goldblum,et al.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[34]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.